Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116.

PMID:
18316791
2.

Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer.

Wang L, Chen X, Li W, Sheng Z.

Anticancer Drugs. 2012 Feb;23(2):155-60. doi: 10.1097/CAD.0b013e32834c3256. Review.

PMID:
21955998
3.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ.

Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Review.

PMID:
20399983
4.

The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.

Bouché O, Beretta GD, Alfonso PG, Geissler M.

Cancer Treat Rev. 2010 Feb;36 Suppl 1:S1-10. doi: 10.1016/S0305-7372(10)00036-8. Review.

PMID:
20189053
5.

Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.

Wu M, Rivkin A, Pham T.

Clin Ther. 2008 Jan;30(1):14-30. doi: 10.1016/j.clinthera.2008.01.014. Review.

PMID:
18343240
6.

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.

Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA.

Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006. Review.

PMID:
21200037
7.

Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer.

Peeters M, Balfour J, Arnold D.

Aliment Pharmacol Ther. 2008 Aug 1;28(3):269-81. Review.

PMID:
19086328
8.

[Panitumumab-treatment of metastatic colorectal cancer].

Pikó B.

Magy Onkol. 2009 Jun;53(2):135-42. doi: 10.1556/MOnkol.53.2009.2.5. Review. Hungarian.

9.

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

Li W, Shi Q, Wang W, Liu J, Ren J, Li Q, Hou F.

Colorectal Dis. 2014 Nov;16(11):O370-8. doi: 10.1111/codi.12749. Review.

PMID:
25155261
10.

Panitumumab: in the treatment of metastatic colorectal cancer.

Hoy SM, Wagstaff AJ.

Drugs. 2006;66(15):2005-14; discussion 2015-6. Review.

PMID:
17100412
11.
12.

KRAS mutation testing in colorectal cancer.

Plesec TP, Hunt JL.

Adv Anat Pathol. 2009 Jul;16(4):196-203. doi: 10.1097/PAP.0b013e3181a9d4ed. Review.

PMID:
19546608
13.

Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.

Chen J, Ye Y, Sun H, Shi G.

Cancer Chemother Pharmacol. 2013 Jan;71(1):265-72. doi: 10.1007/s00280-012-2005-9. Review.

PMID:
23090619
14.

Integration of panitumumab into the treatment of colorectal cancer.

Gravalos C, Cassinello J, García-Alfonso P, Jimeno A.

Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26. doi: 10.1016/j.critrevonc.2009.06.005. Review.

PMID:
19616446
15.

Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis.

Lin AY, Buckley NS, Lu AT, Kouzminova NB, Salpeter SR.

Clin Colorectal Cancer. 2011 Mar 1;10(1):63-9. doi: 10.3816/CCC.2011.n.009. Review.

PMID:
21609938
16.

Panitumumab: in metastatic colorectal cancer with wild-type KRAS.

Weber J, McCormack PL.

BioDrugs. 2008;22(6):403-11. doi: 10.2165/0063030-200822060-00006. Review.

PMID:
18998757
17.

Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status.

Elez E, Alsina M, Tabernero J.

Cancer Treat Rev. 2010 Feb;36 Suppl 1:S15-6. doi: 10.1016/S0305-7372(10)70003-7. Review. No abstract available.

PMID:
20189055
18.

Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.

Song QB, Wang Q, Hu WG.

World J Gastroenterol. 2015 Apr 14;21(14):4365-72. doi: 10.3748/wjg.v21.i14.4365. Review.

19.

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS.

Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Review.

20.

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.

Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL.

Int J Cancer. 2013 Oct 15;133(8):1914-25. doi: 10.1002/ijc.28153. Review. Erratum in: Int J Cancer. 2014 Jul 15;135(2):E2.

Items per page

Supplemental Content

Support Center